The nine core targets identified—TNF, MMP9, IL-6, AKT1, MAPK3, STAT3, SRC, EGFR, and FGF2—were considered for molecular docking, as they are highly involved in pulmonary fibrosis progression, rather than examining 30 targets. This evidence concerns the gene MAPK3 and pulmonary fibrosis.